Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.

Dimitrios C Mastellos1, Edimara S Reis2, Daniel Ricklin3

  • 1Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Division of Biodiagnostic Sciences and Technologies, Institute of Nuclear and Radiological Sciences and Technology, Energy, and Safety (INRASTES), National Center for Scientific Research 'Demokritos', Aghia Paraskevi Attikis, 15310 Athens, Greece.

Trends in Immunology
|April 19, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Production and characterization of gigastasin, a leech-derived inhibitor of complement and coagulation pathways.

Scientific reports·2026
Same author

New Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity.

Journal of medicinal chemistry·2026
Same author

Drug transporter - enzyme crossroads: Does OATP2B1 shape Cyp3a-driven midazolam metabolism in rats?

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Danicopan: complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.

Trends in pharmacological sciences·2025
Same author

Insights Into Atorvastatin Pharmacokinetics in Rats Reveal Regulation of CYP3A1 by Humanization of SLCO2B1.

Pharmacology research & perspectives·2025
Same author

Clinical C3 Inhibition With AMY-101 Reveals Novel Insights Into IL-8-Driven Inflammation in COVID-19.

Immunology·2025
Same journal

IL-33 scripts cancer immunity.

Trends in immunology·2026
Same journal

Mitochondrial Ca<sup>2+</sup> signaling: A metabolic rheostat defining tumor and immune cell fate.

Trends in immunology·2026
Same journal

Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations.

Trends in immunology·2026
Same journal

Gut microbiome metabolites meet immunometabolism in inflammatory bowel disease.

Trends in immunology·2026
Same journal

Metabolic regulatory nodes of the inflammasome and inflammatory cell death.

Trends in immunology·2026
Same journal

Parental leave in immunology - 6.

Trends in immunology·2026
See all related articles
This summary is machine-generated.

Targeting complement component 3 (C3) offers a promising therapeutic strategy for inflammatory diseases like C3 glomerulopathy (C3G). This approach addresses complement imbalance and may provide broader efficacy than current treatments.

Area of Science:

  • Immunology
  • Nephrology
  • Molecular Medicine

Background:

  • Complement dysregulation is implicated in numerous inflammatory disorders.
  • Terminal complement inhibition has shown clinical benefits but is insufficient for emerging pathologies.
  • Genetic variations can influence complement pathways and treatment responses.

Purpose of the Study:

  • To explore the therapeutic potential of modulating complement component 3 (C3) for inflammatory diseases.
  • To highlight C3 intervention as a strategy for complement-driven renal disorders, using C3 glomerulopathy (C3G) as a model.
  • To contextualize concerns regarding long-term C3 inhibition against potential clinical benefits.

Main Methods:

  • Review of current literature on complement dysregulation and therapeutic interventions.
Keywords:
AMY-101C3 glomerulopathyC3 inhibitorsanti-C5 therapyclinical efficacycompstatin

Related Experiment Videos

  • Analysis of C3's role as a central mediator in the complement cascade.
  • Examination of C3 glomerulopathy (C3G) as a case study for C3-targeted therapy.

    • Main Results:

    • C3 acts as a key orchestrator, linking multiple inflammatory pathways.
    • Targeting C3 offers potential for broader therapeutic efficacy compared to terminal complement inhibition.
    • C3 intervention is a developing strategy for complement-mediated kidney diseases like C3G.

    Conclusions:

    • Modulating C3 presents a versatile approach to managing complement-driven inflammatory conditions.
    • Further clinical trials are necessary to evaluate the long-term feasibility and outcomes of C3 inhibition.
    • C3-targeted therapies hold promise for addressing unmet needs in inflammatory and renal disorders.